Content | Navigation |

Former Investigators

Dr. Estelle Leclerc 

Dr. Leclerc ‘s lab is interested in targeting the Receptor for Advanced Glycation End products  (RAGE) in pancreatic cancer. She recently showed in a pre-clinical mouse model of pancreatic cancer, that the combination of RAGE inhibitors with gemcitabine could enhance the efficacy of gemcitabine.

Dr. Guodong Liu      

Dr. Liu has been interested in developing nanomaterial-based platforms for early detection of pancreatic cancer.  His group is involved in developing fast, sensitive, and cost-effective lateral-flow devices for detection of protein and micro-RNA biomarkers present in bodily fluids of pancreatic cancer patients.  

Dr. Mohiuddin Quadir 

Dr. Mohi Quadir is aiming to develop spatially and temporally-responsive drug delivery nano carriers for pancreatic cancer.  The Quadir group is involved in designing linear and dendritic block copolymers that forms nano-sized polymersomes and vesicles capable of encapsulating frontline chemotherapeutic agents and trafficking them to specific cellular compartments without triggering off-target toxicity.

Dr. Katie Reindl  

Dr. Reindl’s research is focused on the roles of small molecule phytochemicals (e.g., piperlongumin) in inducing oxidative stress which kills K-ras oncogene harboring pancreatic cancer cells. The mechanistic details, as well as therapeutic potentials of piperlongumin in  combination of gemcitabine, are being investigated at both cellular and model animal levels.  



Student Focused. Land Grant. Research University.

Follow NDSU
  • Facebook
  • Twitter
  • RSS
  • Google Maps

North Dakota State University
Phone: +1 (701) 231-5192
Campus address: Sudro Hall 102
Physical/delivery address: 1401 Albrecht Blvd, 136 Sudro Hall, Fargo, ND 58102
Mailing address: NDSU Dept. 2665 / PO Box 6050 / Fargo, ND 58108-6050
Page manager: NDSU Department of Pharmaceutical Sciences

Last Updated: Thursday, April 22, 2021 2:44:29 PM
Privacy Statement